-
1.发明授权Method of selective peptide isolation for the identification and quantitative analysis of proteins in complex mixtures 失效选择性肽分离方法用于鉴定和定量分析复杂混合物中的蛋白质公开(公告)号：US07244411B2
公开(公告)日：2007-07-17
申请号：US10988943
申请日：2004-11-15
申请人： Lázaro Hiram Betancourt Núñez , Jorge Fernández de Cossio Dorta-Duque , Vladimir Armando Besada Pérez , Jeovanis Gil Valdés , Luis Javier González López , Gabriel Ramón Padrón Palomares , Rolando Pajón Feyt , Félix Modesto Álvarez Gil
发明人： Lázaro Hiram Betancourt Núñez , Jorge Fernández de Cossio Dorta-Duque , Vladimir Armando Besada Pérez , Jeovanis Gil Valdés , Luis Javier González López , Gabriel Ramón Padrón Palomares , Rolando Pajón Feyt , Félix Modesto Álvarez Gil
CPC分类号： G01N33/6848 , C12Q1/37
摘要： The present invention describes a method of selective peptide isolation for the identification and quantitative analysis of proteins in complex mixture. The method comprises the selective isolation from every protein of those peptides that neither contain arginine nor histidine (NHNR peptides), and the determination of the relative concentrations of one or several proteins in different samples from the ratio between the areas of the estimated theoretical spectra for the NHNR peptides labeled with different isotopes in each sample. The determination of the relative concentration of proteins is valid for any type of isotopic label of the NHNR peptides. The method avoids the separation and purification of the proteins present in a complex mixture, and the analysis of all peptides generated from the enzymatic digest of the samples. The method is applicable to the identification of proteins with vacunal, therapeutic and diagnostic aims.
摘要翻译： 本发明描述了用于鉴定和定量分析复合物中蛋白质的选择性肽分离方法。 该方法包括从不含精氨酸和组氨酸（NHNR肽）的那些肽的每种蛋白质的选择性分离，以及将不同样品中一种或几种蛋白质的相对浓度与估计的理论光谱面积之比 在每个样品中用不同同位素标记的NHNR肽。 蛋白质的相对浓度的测定对于NHNR肽的任何类型的同位素标记是有效的。 该方法避免了复杂混合物中存在的蛋白质的分离和纯化，以及从样品的酶促消化产生的所有肽的分析。 该方法适用于鉴定具有病毒，治疗和诊断目的的蛋白质。
-
2.发明授权Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs 有权用于治疗和/或耐药肿瘤对抗癌药物的化学敏化的药物组合公开(公告)号：US08871725B2
公开(公告)日：2014-10-28
申请号：US12280629
申请日：2007-02-28
申请人： Silvio Ernesto Perea Rodriguez , Yasser Perera Negrin , Arielis Rodriguez Ulloa , Jeovanis Gil Valdés , Yassel Ramos Gómez , Lila Rosa Castellanos Serra , Lázaro Hiram Betancourt Núñez , Aniel Sánchez Puente , Jorge Fernández de Cossio Dorta Duque , Boris Ernesto Acevedo Castro , Luis Javier González López , Vladimir Besada Pérez , Daniel Fernando Alonso , Daniel Eduardo Gomez
发明人： Silvio Ernesto Perea Rodriguez , Yasser Perera Negrin , Arielis Rodriguez Ulloa , Jeovanis Gil Valdés , Yassel Ramos Gómez , Lila Rosa Castellanos Serra , Lázaro Hiram Betancourt Núñez , Aniel Sánchez Puente , Jorge Fernández de Cossio Dorta Duque , Boris Ernesto Acevedo Castro , Luis Javier González López , Vladimir Besada Pérez , Daniel Fernando Alonso , Daniel Eduardo Gomez
CPC分类号： A61K38/08 , A61K31/136 , A61K31/282 , A61K31/337 , A61K31/407 , A61K31/475 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K31/555 , A61K31/675 , A61K31/69 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K31/7076 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.
摘要翻译： 本发明涉及含有酪蛋白激酶2（CK2）肽抑制剂（称为P15）以及癌症治疗中使用的标准化学治疗药物并且分开或依次给药的药物组合。 化疗药物包括顺铂，紫杉醇，长春花生物碱，5-氟尿嘧啶，多柔比星，环磷酰胺，依托泊苷，mitomicin C，伊马替尼，iressa和velcade（vortezomib）。 P15肽与抗癌药物之间的协同作用实现了组合中每种细胞抑制药物的有效浓缩，其比单独的每种细胞抑制药物低10至100倍。 本发明中描述的药物组合物与抗癌治疗剂报道的药物组合物相比表现出较低的毒性，因此它代表其用于癌症治疗的关键优势。 此外，通过用P15肽进行预处理，该药物组合的连续施用导致难治性肿瘤对抗癌治疗剂的化学敏感性。
-
公开(公告)号：US20140206621A1
公开(公告)日：2014-07-24
申请号：US14075276
申请日：2013-11-08
申请人： Maribel Guerra Vallespi , Julio Raúl Fernández Massó , Alexis Musacchio Lasa , Jeovanis Gil Valdés , Osvaldo Reyes Acosta , Brizaida Maylin Oliva Argüelles
发明人： Maribel Guerra Vallespi , Julio Raúl Fernández Massó , Alexis Musacchio Lasa , Jeovanis Gil Valdés , Osvaldo Reyes Acosta , Brizaida Maylin Oliva Argüelles
CPC分类号： C12N15/11 , A61K31/505 , A61K31/513 , A61K33/24 , A61K38/10 , A61K38/1767 , A61K45/06 , A61K48/00 , C07K7/08 , G01N33/574 , A61K2300/00
摘要： This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.
摘要翻译： 本发明描述了通过增加与降低或阻断癌细胞增殖相关的COMMD1蛋白的核定位来治疗癌症的方法。 本发明还涉及在制造用于癌症治疗的药物中增加COMMD1蛋白的核定位的试剂的用途。 这些试剂可以是其他化合物中的肽或蛋白质。 本发明还涉及来自序列HARIKPTFRRLKWKKYKGKFW的肽的优化，以增加蛋白质COMMD的核定位，从而提高该肽的抗肿瘤效果。
-
公开(公告)号：US08729226B2
公开(公告)日：2014-05-20
申请号：US13700286
申请日：2011-05-31
申请人： Maribel Guerra Vallespi , Julio Raúl Fernández Massó , Alexis Musacchio Lasa , Jeovanis Gil Valdés , Osvaldo Reyes Acosta , Brizaida Maylin Oliva Argüelles
发明人： Maribel Guerra Vallespi , Julio Raúl Fernández Massó , Alexis Musacchio Lasa , Jeovanis Gil Valdés , Osvaldo Reyes Acosta , Brizaida Maylin Oliva Argüelles
IPC分类号： A61K38/00
CPC分类号： C12N15/11 , A61K31/505 , A61K31/513 , A61K33/24 , A61K38/10 , A61K38/1767 , A61K45/06 , A61K48/00 , C07K7/08 , G01N33/574 , A61K2300/00
摘要： This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.
摘要翻译： 本发明描述了通过增加与降低或阻断癌细胞增殖相关的COMMD1蛋白的核定位来治疗癌症的方法。 本发明还涉及在制造用于癌症治疗的药物中增加COMMD1蛋白的核定位的试剂的用途。 这些试剂可以是其他化合物中的肽或蛋白质。 本发明还涉及来自序列HARIKPTFRRLKWKKYKGKFW的肽的优化，以增加蛋白质COMMD的核定位，从而提高该肽的抗肿瘤效果。
-
公开(公告)号：US20130224313A1
公开(公告)日：2013-08-29
申请号：US13700286
申请日：2011-05-31
申请人： Maribel Guerra Vallespi , Julio Raúl Fernández Massó , Alexis Musacchio Lasa , Jeovanis Gil Valdés , Osvaldo Reyes Acosta , Brizaida Maylin Oliva Argüelles
发明人： Maribel Guerra Vallespi , Julio Raúl Fernández Massó , Alexis Musacchio Lasa , Jeovanis Gil Valdés , Osvaldo Reyes Acosta , Brizaida Maylin Oliva Argüelles
IPC分类号： A61K38/10 , A61K31/513 , A61K33/24 , G01N33/574 , A61K48/00 , C07K7/08
CPC分类号： C12N15/11 , A61K31/505 , A61K31/513 , A61K33/24 , A61K38/10 , A61K38/1767 , A61K45/06 , A61K48/00 , C07K7/08 , G01N33/574 , A61K2300/00
摘要： This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.
摘要翻译： 本发明描述了通过增加与降低或阻断癌细胞增殖相关的COMMD1蛋白的核定位来治疗癌症的方法。 本发明还涉及在制造用于癌症治疗的药物中增加COMMD1蛋白的核定位的试剂的用途。 这些试剂可以是其他化合物中的肽或蛋白质。 本发明还涉及来自序列HARIKPTFRRLKWKKYKGKFW的肽的优化，以增加蛋白质COMMD的核定位，从而提高该肽的抗肿瘤效果。
-
6.发明申请Methods and Proteins for the Prophylactic and/or Therapeutic Treatment of Four Serotypes of Dengue Virus and Other Flaviviruses 审中-公开用于预防和/或治疗四种登革热病毒和其他黄病毒血清型的方法和蛋白质公开(公告)号：US20090312190A1
公开(公告)日：2009-12-17
申请号：US12094503
申请日：2006-11-21
申请人： Glay Chinea Santiago , Vivian Huerta Galindo , Alejandro Miguel Martin Dunn , Jorge Victor Gavilondo Cowley , Noralvis Fleitas Salazar , Osmany Guirola Cruz , Jeovanis Gil Valdés , Aída Zulueta Morales , Lisset Hermida Cruz , Marta Ayala Avila , Diamilé Gonzáles Roche , Rolando Paez Meireles , Patricia Gabriela Toledo Mayora , Mónica Sarria Núnez , Alexis Musacchio Lasa , Yuliet Mazola Reyes
发明人： Glay Chinea Santiago , Vivian Huerta Galindo , Alejandro Miguel Martin Dunn , Jorge Victor Gavilondo Cowley , Noralvis Fleitas Salazar , Osmany Guirola Cruz , Jeovanis Gil Valdés , Aída Zulueta Morales , Lisset Hermida Cruz , Marta Ayala Avila , Diamilé Gonzáles Roche , Rolando Paez Meireles , Patricia Gabriela Toledo Mayora , Mónica Sarria Núnez , Alexis Musacchio Lasa , Yuliet Mazola Reyes
IPC分类号： C40B30/02 , A61K39/00 , A61K39/12 , C12N7/00 , C12N5/00 , C40B30/04 , C40B40/10 , C07K16/00 , C07H21/04 , A61K39/02
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K2039/55566 , C07K2319/02 , C07K2319/21 , C12N2770/24022 , C12N2770/24122 , C12N2770/24134 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/394 , Y02A50/396
摘要： The present invention is related to the field of the pharmaceutical industry, and describes a conserved area on the surface of the E protein that can be used for the development of wide-spectrum antiviral molecules to be employed in the prophylaxis and/or treatment of infections due to Dengue Virus serotypes 1-4 and other flaviviruses. The invention also covers chimeric proteins to be used as vaccines or as a prophylactic or therapeutic treatment against the four serotypes of Dengue Virus and other flaviviruses.
摘要翻译： 本发明涉及制药工业的领域，并且描述了可用于开发用于预防和/或治疗感染的广谱抗病毒分子的E蛋白表面上的保守区域 由于登革热病毒血清型1-4和其他黄病毒。 本发明还涵盖用作疫苗的嵌合蛋白或针对登革热病毒和其他黄病毒的四种血清型的预防或治疗性治疗。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.035 秒)
